STOCK TITAN
  1. Home
  2. News
  3. PFE

Pfizer Inc. - PFE STOCK NEWS

Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.

Pfizer Inc. (PFE), headquartered at The Spiral in Manhattan, New York City, is a leading American multinational pharmaceutical and biotechnology corporation established in 1849 by Charles Pfizer and his cousin Charles F. Erhart. Pfizer stands as one of the world's largest pharmaceutical companies, with annual sales nearing $50 billion, excluding COVID-19 product sales.

Pfizer's core business revolves around the development, manufacturing, and global distribution of prescription drugs and vaccines. Its top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. These products contribute significantly to Pfizer's global sales, with nearly 50% of revenues coming from international markets, and emerging markets playing a crucial role.

In recent news, Pfizer continues to make strides in cancer treatment through its collaboration with Astellas and Merck. A key focus has been on the promising cancer therapeutic combinations involving PADCEV™ (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab), targeting metastatic urothelial cancer. This collaboration underscores Pfizer's commitment to advancing cancer treatments and improving patient outcomes worldwide.

Financially, Pfizer remains robust, continually investing in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs. Strategic partnerships and collaborations further enhance its position in the market, ensuring a steady pipeline of new and effective therapeutic solutions.

With a rich history and a steadfast commitment to healthcare innovation, Pfizer Inc. continues to be a significant player in the pharmaceutical industry, dedicated to improving global health through advanced medical research and groundbreaking therapies.

News

Pfizer Provides Full-Year 2024 Guidance

Rhea-AI Summary
Pfizer Inc. (NYSE:PFE) provided full-year 2024 revenue guidance of $58.5 to $61.5 billion, including the expected contribution from Seagen acquisition. The company anticipates approximately $8 billion in revenues for Comirnaty and Paxlovid. Pfizer expects operational revenue growth of 8%-10% in 2024, including Seagen contribution, and 3%-5% excluding both Seagen contribution and Comirnaty and Paxlovid revenues. Adjusted diluted EPS guidance is $2.05 to $2.25, reflecting operational revenue growth and cost savings from the realignment program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
none
-
News

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Rhea-AI Summary
Pfizer Inc. (PFE) is set to close the acquisition of Seagen Inc. (SGEN) on December 14, 2023, after receiving all required regulatory approvals. The company also announced changes in its commercial organization to incorporate Seagen and improve focus, speed, and execution. Pfizer will host an analyst and investor call to discuss the acquisition, new commercial organization, and provide full-year 2024 financial guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
acquisition
-
News

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) announced that the FDA has accepted the BLA for marstacimab, a potential once-weekly subcutaneous treatment for hemophilia A and B without inhibitors to Factor VIII or Factor IX. The European MAA for marstacimab also passed validation. The FDA has set a PDUFA action date in Q4 2024, and a decision from the European Commission is anticipated by Q1 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
News

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

Rhea-AI Summary
Pfizer Inc. (PFE) presented results from the pivotal Phase 3 BASIS clinical trial evaluating marstacimab for the treatment of severe hemophilia A and moderately severe to severe hemophilia B without inhibitors to Factor VIII (FVIII) or Factor IX (FIX). The trial demonstrated a 35% reduction in annualized bleeding rate compared to routine prophylaxis and a 92% reduction compared to on-demand treatment. The results were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.49%
Tags
clinical trial
-
News

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

Rhea-AI Summary
Pfizer Inc. (PFE) has received conditional marketing authorization from the European Commission for ELREXFIO (elranatamab), a targeted immunotherapy for adult patients with relapsed and refractory multiple myeloma. The authorization is based on meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial, showing significant response rates among heavily pretreated patients. The product is an off-the-shelf, fixed-dose, subcutaneous BCMA-directed bispecific antibody immunotherapy with reduced dosing after 24 weeks for responding patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
none
-
News

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Rhea-AI Summary
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial for its oral GLP-1RA candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint, demonstrating statistically significant change in body weight from baseline. The twice-daily dosing of danuglipron showed statistically significant reductions in body weight for all doses, with mean reductions ranging from -6.9% to -11.7% at 32 weeks, and -4.8% to -9.4% at 26 weeks, compared to +1.4% for placebo at 32 weeks, and +0.17% for placebo at 26 weeks. The most common adverse events were mild and gastrointestinal in nature, but high rates were observed. High discontinuation rates, greater than 50%, were seen across all doses compared to approximately 40% with placebo. Pfizer will focus on developing a once-daily formulation of danuglipron to improve its tolerability profile and study design.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
clinical trial
News

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Rhea-AI Summary
Pfizer Inc. (PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 10:50 a.m. EST. The webcast can be accessed on Pfizer's investor website, with the transcript and webcast replay available within 24 hours after the live discussion and accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
conferences
-
News

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Rhea-AI Summary
PFE and Astellas Pharma Inc. (4503) announced that the FDA approved a supplemental New Drug Application for XTANDI, making it the first and only androgen receptor signaling inhibitor approved for nonmetastatic castration-sensitive prostate cancer treatment with or without a GnRH analog therapy. This approval follows expedited development and review programs based on results from the Phase 3 EMBARK trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.5%
Tags
none
-
News

Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting

Rhea-AI Summary
Pfizer Inc. will present data on advancements in the treatment of hemophilia, sickle cell disease, and blood cancers at the ASH Annual Meeting. Key presentations include results from the Phase 3 BASIS trial of marstacimab in hemophilia, Phase 2/3 results from the GBT601 study in sickle cell disease, and data on ELREXFIO for multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
none
News

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Rhea-AI Summary
Pfizer Inc. invites investors and the general public to view a webcast of a discussion with Aamir Malik, Chief Business Innovation Officer, Executive Vice President, at the Truist Securities BioPharma Symposium on November 9, 2023. The webcast will be available on Pfizer's website and the transcript and replay will be accessible for at least 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
conferences

FAQ

What is the current stock price of Pfizer (PFE)?

The current stock price of Pfizer (PFE) is $26.41 as of January 14, 2025.

What is the market cap of Pfizer (PFE)?

The market cap of Pfizer (PFE) is approximately 151.1B.

What is Pfizer Inc. known for?

Pfizer Inc. is known for its development, manufacturing, and distribution of prescription drugs and vaccines, including Prevnar 13, Ibrance, and Eliquis.

Where is Pfizer's headquarters located?

Pfizer's headquarters are located at The Spiral in Manhattan, New York City.

How much does Pfizer make annually?

Pfizer's annual sales are close to $50 billion, excluding COVID-19 product sales.

What are some of Pfizer's top-selling products?

Some of Pfizer's top-selling products include the pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

What is the significance of Pfizer's international sales?

Pfizer's international sales represent nearly 50% of its total sales, with emerging markets being a major contributor.

What recent collaborations has Pfizer been involved in?

Pfizer has recently been involved in collaborations with Astellas and Merck to develop and commercialize cancer treatments like PADCEV™ and KEYTRUDA®.

When was Pfizer founded?

Pfizer was founded in 1849 by Charles Pfizer and Charles F. Erhart.

What is Pfizer's approach to innovation?

Pfizer continually invests in research and development to innovate and expand its portfolio of treatments addressing unmet medical needs.

How does Pfizer contribute to cancer treatment?

Pfizer contributes to cancer treatment through its development of innovative therapies and strategic collaborations, notably involving PADCEV™ and KEYTRUDA®.

What role do strategic partnerships play for Pfizer?

Strategic partnerships enhance Pfizer's market position, ensuring a steady pipeline of new and effective therapeutic solutions.
Stock PFE logo
Pfizer Inc.

NYSE:PFE

PFE Rankings

#70 Ranked by Market Cap
#420 Ranked by Dividends

PFE Stock Data

151.15B
5.66B
0.05%
67.79%
1.51%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NEW YORK